ALKERMES | ALKS - 债务利息支出

金融业

USD

USD 4.26B

现金及等价物

USD 351.55M

USD 73.25M

USD 1.36B

USD 599.5M

USD 1.58B

股息收益率

0

USD -48.28M

USD 80.26M

1.8K

EPS每股收益

USD -0.4

股本和储备

USD 1.75B

USD 331.33M

债务利息支出

USD 20.89M

USD 8.54M

USD 1.48B

USD 7.02B

USD -66.48M

USD 1.75B

USD -48.28M

普通股股本

USD 166.46M

39.33

USD -61.93M

USD 392.91M

销售和管理费用

USD 264.59M

USD 336.7M

贸易债权人

USD 102.36M

应收帐款人

USD 407.63M

	债务利息支出	更改		日
AbbVie	USD 645M		69M	2026-03
Acadia Pharmaceuticals	USD 0		4.12M	2024-09
ALKERMES	USD 20.89M		8.62M	2026-03
Amgen	USD 657M		4M	2026-03
Biogen	USD 72.6M		12.6M	2025-06
BioMarin Pharmaceutical	USD 14.96M		12.18M	2026-03
Bristol-Myers Squibb	USD 411M		21M	2026-03
Coherus Biosciences	USD 2.25M		76K	2025-12
Eli Lilly	USD 114.7M		134.3M	2025-09
Gilead Sciences	USD 240M		15M	2026-03
Heron Therapeutics	USD 600K		100K	2024-12
Ionis Pharmaceuticals	USD 17M		1000K	2026-03
J&J	USD 43M		25M	2026-03
Merck	USD 479M		67M	2026-03
Minerva Neurosciences	USD 2.31M		60K	2024-06
Nektar Therapeutics	USD 9.77M		3.75M	2025-12
Neurocrine Biosciences	USD 1.1M		0	2024-03
Otsuka Holdings	JPY 2.21B		866M	2025-12
Ovoca Bio	EUR 7K		6K	2022-06
Pfizer	USD 671M		40M	2026-03
Regeneron Pharmaceuticals	USD 12.9M		700K	2026-03
Vertex Pharmaceuticals	USD 3.3M		0	2025-12